Tandem Diabetes CareLTS:0M0F 69 Days Payable is 44.18 as of Mar. 2026, which is 22% above its 10-year median of 36.07. GuruFocus rates LTS:0M0F with a GF Score™ of 69/100 and a GF Value™ of $29.77 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Tandem Diabetes Care ranks worse than 73.46% on this metric.
The historical rank and industry rank for Tandem Diabetes Care's Days Payable or its related term are showing as below:
LTS:0M0F'
s Days Payable Range Over the Past 10 Years
Min: 23.24 Med: 36.07 Max: 50.58
Current: 42.56
During the past 13 years, Tandem Diabetes Care's highest Days Payable was 50.58. The lowest was 23.24. And the median was 36.07.
LTS:0M0F's Days Payable is ranked worse than 73.46% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs LTS:0M0F: 42.56
Tandem Diabetes Care's Days Payable
increased
from Mar. 2025 (41.11) to Mar. 2026 (44.18).
It may suggest that Tandem Diabetes Caredelayed paying its suppliers.
Tandem Diabetes Care Days Payable Related Terms
Tandem Diabetes Care Days Payable Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0M0F vs CNMD, AORT, LMRI: Days Payable Comparison
For the Medical Devices subindustry, Tandem Diabetes Care's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Days Payable distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Tandem Diabetes Care's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care (LTS:0M0F) has a Days Payable of 44.18 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tandem Diabetes Care and its competitors. This is 22% above median its historical median of 36.07. Over the past decade, Tandem Diabetes Care's Days Payable has ranged from 23.24 to 50.58. According to the industry distribution chart, Tandem Diabetes Care ranks #584 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 73.5%.
Is Tandem Diabetes Care's Days Payable too high?
Tandem Diabetes Care's current Days Payable of 44.18 is 22% above median its 10-year median of 36.07. Over the past 10 years, this metric has ranged from a low of 23.24 to a high of 50.58. The Medical Devices & Instruments industry median Days Payable is 68.07. Tandem Diabetes Care's value of 44.18 is 35.1% below this industry median. Based on the distribution chart, Tandem Diabetes Care ranks #584 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Tandem Diabetes Care has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Days Payable compare to CNMD and AORT?
According to the Medical Devices & Instruments industry distribution chart, Tandem Diabetes Care ranks #584 out of 795 companies for Days Payable. This places Tandem Diabetes Care in the lower half of its industry. The industry median Days Payable is 68.07. Tandem Diabetes Care's value of 44.18 is 35.1% below this benchmark. Historically, Tandem Diabetes Care's own Days Payable has ranged from 23.24 to 50.58 over the past decade. While the company's 10-year median is 36.07 vs. the industry median of 68.07, Tandem Diabetes Care has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tandem Diabetes Care's current Days Payable of 44.18 is 35.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tandem Diabetes Care and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tandem Diabetes Care's current Days Payable is 44.18, which is 22% above median its own 10-year median of 36.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.77, compared to a current price of $15.63 — trading 47.5% below its estimated fair value. The current Days Payable is 44.18, which is 22% above median its 10-year median of 36.07 and 35.1% below the Medical Devices & Instruments industry median of 68.07. Tandem Diabetes Care's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Days Payable is 44.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of $15.63 is trading 47.5% below its estimated GF Value™ of $29.77.
GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.
Key valuation signals for LTS:0M0F:
Days Payable: 44.18 (22% above median its 10-year median of 36.07)
GF Value™: $29.77 vs. price of $15.63 (47.5% below fair value)
Industry Position: 35.1% below the Medical Devices & Instruments median (#584 of 795)
No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
69GF Score
Get the complete analysis for LTS:0M0F
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M0F has been successfully added to your 
